- $2.62m
- $8.44m
- $0.05m
U.S. STOCKS ON THE MOVE-HCW Biologics, Talen Energy
HCW Biologics rises as US FDA approves trial for hair loss treatment
Brief: Hcw Biologics Prices $6.9 Mln Registered Direct Offering And Concurrent Private Placement At $1.03 Per Share
Brief: HWC Biologics Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon
Brief: HCW Biologics Exercised Right To Terminate Credit Agreement With Prime Capital Ventures
Brief: Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Brief: HCW Biologics - On Aug 29, Granted U.S. Patent Which Contains Claims For Method Of Promoting Activation, Proliferation Of Natural Killer Cells
Brief: HCW Biologics Granted Third Fundamental Patent
Brief: Hcw Biologics Reports Q1 C2023 Financial Results And Recent Business Highlights
Brief: HCW Biologics Secures $26.25 Mln Non-Dilutive Financing
Brief: Hcw Biologics Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Business Highlights
Brief: HCW Biologics Enters Crada With National Cancer Institute
Brief: HCW Biologics Granted Second Fundamental Patent
Brief: Masonic Cancer Center, University Of Minnesota To Present Phase 1 Clinical Trial Data For Hcw9218 In Solid Tumors
Brief: HCW Biologics Inc Reports Quarterly Net Loss Per Share Of $0.11
Brief: HCW Biologics Files For Mixed Shelf Of Up To $100 Million
Brief: HCW Biologics reports Q2 results
Brief: Hcw Biologics Inc Says Masonic Cancer Center Announced First Patient Was Dosed In Phase 1 Clinical Trial To Evaluate HCW9218
Brief: Hcw Biologics Reports First Quarter 2022 Financial Results And Recent Business Highlights